Acer Therapeutics

Acer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS).  The company was founded in 2013 and is headquartered in Newton, Massachusetts.

NEWTON, Mass., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September, including the LD Micro 500 Virtual Conference and the H.C. Wainwright 22nd Annual Global Investment Conference.

Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders

Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO & NEWTON, Mass.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc.

Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss

SAN DIEGO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934. Acer is a pharmaceutical company that focuses on the development and commercialization of therapies for rare diseases. One of its medications is EDVISO (celiprolol) for the trea

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)

Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current treatments

Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study

LOS ANGELES--(BUSINESS WIRE)---- $ACER #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (“Acer” or the “Company”) (NASDAQ: ACER) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On June 25, 2019, the Company disclosed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration rejecting its new drug application for EDSIVO,

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc.

Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital

Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

NEWTON, Mass., April  30, 2020  (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.

Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital

Lenovo Group Ltd

Apple

Dell Technologies

Per IDC, PC shipments decline 9.8% in Q1 despite strong demand, as the global lockdown hurt supply chains and productions all over.

PC Shipments Slide in Q1 as Coronavirus Disrupts Supply Chain

Acer Therapeutics: EDSIVO Appeal Denied But FDA Door Remains Open

Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™ Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™

Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs

Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data

Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®

Acer Therapeutics: Upcoming Catalysts

Part A Successfully Completed and Optimal Formulation of ACER-001 Identified

Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021 Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

There are several good reasons that two consecutive quarters of improved personal computer purchases could become three, and then four, or more.

Solid PC Sales in Q3 Bolsters Bullish Case for HP, Dell

Acer's share price plummeted following a CRL issued by the FDA in late June for Acer's lead drug candidate EDSIVO for the treatment of vEDS patients with COL3A1 + mutation.

Acer Therapeutics: Undervalued With A Free Call Option On EDSIVO

NEWTON, Mass., Aug.  27, 2019  (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on Tuesday, September 10, 2019.

Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Biohaven Pharmaceutical Hld

Celgene

Intra-Cellular Therapies

Karyopharm Therapeutics

Merck

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Attention Biotech Investors: Mark Your Calendar For These July 2019 PDUFA Dates

Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

Acer Shares Down on FDA's CRL for Genetic Disorder Treatment

Acer Therapeutics news for Tuesday concerning a rejection letter from the U.S. Food and Drug Administration is pummeling ACER stock.

Acer Therapeutics News: ACER Stock Plunges on FDA Rejection

Acer Therapeutics Inc (NASDAQ: ACER) shares were trading down more than 75% Tuesday after it received a letter from the Food and Drug Administration regarding its drug application for Edsivo in the treatment of vascular Ehlers-Danlos syndrome.

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Acer Therapeutics Inc. said Tuesday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its new drug application (NDA) for Edsivo, a treatment of vascular Ehlers-Danlos syndrome (vEDS).

Acer Therapeutics receives CRL from FDA for Edsivo, stock halted for news

Acer Therapeutics has 3 clinical stage drug candidates targeting serious orphan and ultra-orphan diseases with significant unmet medical needs.

Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date

Laura Chico maintained an Outperform rating on Acer Therapeutics with an unchanged $48 price target.

News for Acer Therapeutics Stock (ACER)